Unlike typical drugs with inelastic demand, the market for GLP-1s is price-elastic. Eli Lilly's CEO confirms that lowering prices directly expands the user base, creating a rare instance where capitalist incentives align with broader consumer access in the pharmaceutical industry.

The GLP-1 market is projected to face intense competition from both generics (like statins) and high-rebate branded drugs (like ED medications). This dual pressure will squeeze profit margins, drive net prices down significantly, and ultimately compel broad payer coverage due to the drugs' strong clinical return on investment.

The two pharma giants are competing aggressively in the direct-to-consumer channel. They're cutting prices on their GLP-1 drugs, anticipating that lower costs will drive significantly higher volume and sales in the long run, even if it hurts short-term revenue forecasts.

The obesity drug market is seeing prices cut in half much faster than anticipated, despite being a duopoly. This rapid price degradation is driven by Novo Nordisk, the market laggard, aggressively using price as a weapon to reclaim market share from Eli Lilly, a dynamic typically seen only after multiple new players enter.

The introduction of oral GLP-1 medications is proving to be a market expansion strategy, not a cannibalization one. Data shows that the majority of patients starting on oral versions are new to the GLP-1 category entirely, indicating the new form factor overcomes a key barrier to adoption.

Despite concerns about cannibalizing its injectable user base, Novo Nordisk found that approximately 80% of patients taking the new Wegovy pill are new to the treatment segment. This demonstrates that introducing a new form factor can be a powerful market expansion strategy.

India produces 60% of the world's drugs by volume but captures only 2-5% of the revenue. This disparity exists because it dominates the post-patent generic market, where prices can fall by over 95%, while innovator companies capture the high-margin monopoly period.

The introduction of low-cost generic semaglutide in India revealed massive pent-up demand. Volumes surged sixfold in just two months, driving such significant market expansion that the total market value is projected to grow eightfold by 2030, even with lower per-unit prices.

Despite the arrival of low-cost generic semaglutide, superior drugs like Tirzepatide, which offers better efficacy and tolerability, can command premium prices. This creates a durable, high-value market segment that coexists with, rather than being eroded by, cheaper alternatives.